Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Lifastuzumab Biosimilar - Anti-SLC34A2 mAb - Research Grade |
---|---|
Source | CAS 1401812-88-1 |
Species | Humanized |
Expression system | Mammalian cells |
Purity | >85% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Applications | ELISA,WB |
Aliases /Synonyms | Lifastuzumab,DNIB0600A (conjugate),MNIB2126A (non conjugate),SLC34A2,anti-SLC34A2 |
Reference | PX-TA1334 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1-kappa |
Clonality | Monoclonal Antibody |
Lifastuzumab is investigated for the treatment of Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer.
Lifastuzumab Biosimilar - Anti-SLC34A2 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Related products
Reviews
Il n’y a pas encore d’avis.